

BÖLÜM 24



Plevranın Malign Tümörleri ve Cerrahi Tedavisi

Süleyman Anıl AKBOĞA¹
Bülent KOÇER²

Giriş

Plevra eski Yunancada “pleuron” yan-kanat anlamındadır. Membran olarak ilk kez Aristo'nun “History of Animals” kitabında tanımlanmıştır. Plevranın kendine ait birçok hastalığı olduğu gibi akciğer dışındaki birçok hastalıkta plevrayı etkileyerek hastalık meydana getirebilmektedir. Başta mezotelyoma olmak üzere, plevranın malign hastalıkları yüksek mortalite ile seyretmesi sebebiyle ayrı bir öneme sahiptir.

Plevranın malign tümörleri oldukça nadir görülmektedir. En sık görülen malign plevral tümör malign plevral mezotelyomadır (MPM). Ayrıca plevranın mezotelyoma dışında sarkom (kondrosarkom, leiomyosarkom, liposarkom rabdomyosarkom), melanom, lenfoma, malign fibroz histiyositom, skuamöz

hücreli karsinom, mezoderm ve küçük hücreli karsinom gibi oldukça nadir görülen malign tümörleride mevcuttur (1).

Tablo 1. Plevranın Malign Tümörleri

1. **Malign Plevral Mezotelyoma (%90)**
2. Sinoviyal sarkom
3. Epiteloid hemanjiyo-endoteliyoma
4. Malign Fibröz Histiyositom
5. Anjiosarkom
6. Kondroblastik osteosarkomu
7. Primer düz kas tümörü
8. Plevranın primer kondrosarkomu
9. Primer plevral timoma
10. Plevranın primer skuamöz hücreli karsinomu
11. Plevranın adenoskuamöz karsinomu
12. Hemanjioperisitom
13. Primer plevral liposarkom
14. Malign periferik sinir kılıfı tümörü
15. Plevranın mukoepidermoid tümörü
16. Plevranın Primer Melanomu

¹ Uzm. Dr., Sağlık Bilimleri Üniversitesi, Ankara Şehir Hastanesi Göğüs Cerrahisi Kliniği, doktor_anil_@hotmail.com

² Prof. Dr., Sağlık Bilimleri Üniversitesi, Ankara Şehir Hastanesi Göğüs Cerrahisi Kliniği, drbkocer@gmail.com

gözde tümör olmaması ile birlikte plevrada soliter lezyon olması gerekmektedir (54,58).

Primer Plevral Lenfoma

Lenfoma tanısı alan hastalarda plevrada lenfomaya sekonder gelişen lezyonların görülmesi nadir bir durum değildir (63). Fakat lenfomanın primer olarak plevradan köken aldığı olgular literatürde tüm lenfomaların %7'lik bir kısmını oluştururlar (64). Tedavide primer olarak kemoterapi uygulanmaktadır. Hastaların sağ kalımı ve prognozu üzerine tedavi oldukça etkindir (65).

Plevranın Primer Skuamöz Hücreli Karsinomu

Oldukça nadir görülen bir histopatolojik alt tip olan primer plevral skuamöz hücreli karsinom mezotelyomadan mutlaka ayırt edilmelidir. Skuamöz hücreli karsinom p63 ve p40 pozitif boyanırken mezotelyoma da pozitif değildir. Tedavisi net olarak bilinmemekle birlikte tümör cerrahi olarak rezeke edilebiliyorsa öncelikle komplet rezeksiyon düşünülmelidir (66).

Plevranın Primer Adenoskuamöz Hücreli Karsinomu

Oldukça nadir görülürler. Mezotelyoma ile ayırıcı tanısında musin boyası kullanılır. Tedavide primer yaklaşım kemoterapidir. Sağ kalımı 6-8 aydır ve prognozu ise kötüdür (54). Ayrıca plevrada primer olarak görülen bahsettiğimiz bu tümörlerin dışında literatürde sadece birkaç olgu ile bahsedilmiş olan hemangioperisitom, malign periferik sinir kılıfı tümörü ve plevral mukoepidermoid tümör gibi çok nadir görülen primer plevral malign karakterli tümörler de mevcuttur.

KAYNAKLAR:

1. Gokce A., Kocer B. Olgular İle Plevra Hastalıkları ve Cerrahi Tedavisi. Akademisyen 2021/7 279-298
2. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011; 89: 716-24, 724A-724C.
3. Berk S, Yalcin H, Dogan OT, Epozturk K, Akkurt I, Seyfikli Z. The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province, Turkey. Environ Geochem Health. 2014 Feb;36 (1):55-64.
4. Bianchi C, Bianchi T. Global mesothelioma epidemic: Trend and features. Indian J Occup Environ Med. 2014;18 (2):82-88.
5. Türkiye Mezotelyoma Çalışma Grubu. Malign Plevral Mezotelyoma Türkiye Standartlar Rehberi. Eskişehir: ESOGÜ-APKAM; 2014:1-224.
6. Kane A: Mechanism of mineral fibre carcinogenesis. In Kane AB, Bofetta P, Saracci R(eds). Mechanism of fiber carcinogenesis. Lyon, France, IARC Scientific Publications, 1996
7. Shan KV: Causality of mesothelioma:SV40 question. ThoracSurgClin 14:497-504.
8. World Health Organisation (WHO). Elimination of asbestos-related diseases. Geneva: WHO; 2006
9. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591- 603.
10. Farioli A, Ottone M, Morganti AG, Compagnone G, Romani F, Cammelli S, et al. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Medicine 2016; 5 (5):950-959.
11. Baris I, Simonato L, Artvinli M, Pooley F, Saracci R, Skidmore J, Wagner C. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer 1987; 39: 10-17.
12. Robinson BWS, Msk AW, Lake RA. Malignant Mesothelioma. Lancet 2005; 366: 397-08
13. Arslan S. "Malign Plevral Mezotelyoma". (yucel O, Genc P edit), "Plevra Hastalıkları ve Tedavisi", Journal of Clinical and AnalyticMedicine, JCAM kitap serisi,, 2010;1-5
14. MeerbeecJP, Scherpered A, Surmont VF; Baas P. Malignant PlevralMesotelioma. The standart of careandchallenges for future manegment. ClinicalReviews in Oncology/Hematology 2011;78:92-11
15. R.E. Benamore, M.J. O'Doherty, J.J. Entwisle. REVIEW: Use of imaging in the management of malignant pleural mesothelioma.ClinicalRadiology (2005) 60, 1237- 1247
16. Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. Am J Roentgenol 1990;154(3):487-92.

17. Metintaş M. Malign Mezotelyoma. Göze G, Köktürk O (Edit). Plevra Hastalıkları. Turgut Yayıncılık, İstanbul. 2003;4:230-59
18. Metintas M, Uçgun I, Elbek O, Erginel S, Metintas S, Kolsuz M, et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. *Eur J Radiol* 2002;41:1-9.
19. Gill RR, Umeoka S. Diffusion-weighted MRI of malignant pleural mesothelioma preliminary assessment of apparent diffusion coefficient in histologic subtypes. *AJR Am J Roentgenol* 2010; 195 (2): 125-30.
20. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. *J Thorac Cardiovasc Surg* 2003; 126 (1): 11-6.
21. Mc Laughlin KM, Kerr KM, Currie GP. Closed pleural biopsy to diagnose mesothelioma: Dead or alive? *Lung Cancer* 2009; 65 (3):388-9.
22. Ermerak O, Batirel HF. Diffüz malign plevral mezotelyoma: invaziv tanı yöntemleri. *Türkiye Klinikleri J Thor Surg-Special Topics* 2011;4 (1):45-9.
23. Van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. *J Thorac Dis* 2013;5:E254-307.
24. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J* 2010; 35 (3): 479-95
25. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumectomy in the Management of Diffuse Malignant Mesothelioma of the Pleura. Experience With 29 Patients *Thorax* 1976;31 (1):15-24.
26. Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, et al. Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database. *J Thorac Oncol.* 2012;7:1631-9.
27. CS Ng, Munden RF, Libshitz HI. Malignant pleural mesothelioma: the spectrum of manifestations on CT in 70 cases. *Clin Radiol* 1999;54:415-21.
28. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. *J Thorac Cardiovasc Surg* 2008;135:620-6.
29. Kim S, Bull D A, Garland L, Khalpey Z, Stea B, et al. Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma? *Ann Thorac Surg.* 2019 Jan;107 (1):194-201.
30. Ettinger DS, Wood DE, Akerley W, et al. Induction chemoradiation in stage IIIA/N2 non-small cell lung cancer: A phase 3 randomised trial. *Lancet* 2015;386:1049-56.
31. Kindler HL, Ismaila N, Armato 3rd SG, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2018;36:1343-73.
32. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J* 2010;35:479-95
33. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. *Thorax* 1976;31:15-24.
34. Sugarbaker DJ, Wolf AS, Chirieac LR, et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. *J Thorac Cardiovasc Surg* 1991;102:10-5
35. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016. *J Natl Compr Cancer Netw* 2016;14:825-36
36. Sandri A, Guerrero F, Roffinella m, et al. Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma. *J Thorac Dis* 2016;8:2121.
37. Opitz I, Friess M, Kestenholz P, et al. A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: a review of 12 years' experience. *J Thorac Oncol* 2015;10:1634-41.
38. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. *J Thorac Cardiovasc Surg* 2004;128:138-46.
39. Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. In: *Seminars in thoracic and cardiovascular surgery.* Elsevier 2009. 132-48.
40. Zellos L, Jaklitsch MT, Al-Mourgi MA, et al. Complications of extrapleural pneumonectomy. In: *Seminars in thoracic and cardiovascular surgery.* Elsevier 2007. 355-9.
41. Schneider D, Grodzki T, Lardinois D, et al. Accelerated treatment of postpneumectomy empyema: a binational long-term study. *J Thorac Cardiovasc Surg* 2008;136:179-85
42. Flores R M, Pass H I, Seshan V E, Dycoco J, Zakowski M, et al. Extrapleural Pneumectomy Versus pleurectomy/decortication in the Surgical Management of Malignant Pleural Mesothelioma: Results in 663 Patients. *J Thorac Cardiovasc Surg.* 2008 Mar;135 (3):620-6, 626.e1-3.
43. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. *Lancet Oncol* 2011;12:763-72
44. Weder W, Stahel RA, Baas P, et al. The MARS feasibility trial: conclusions not supported by data. *Lancet Oncol* 2011;12:1093-4.

45. Rusch V W, Giroux D, Kennedy C, Ruffini E, Cangir A K, et al. IASLC Staging Committee. Initial Analysis of the International Association for the Study of Lung Cancer Mesothelioma Database. *J Thorac Oncol*. 2012 Nov;7 (11):1631-9.
46. Cao C, Tian D, Park J, et al. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. *Lung cancer* 2014;83:240-5.
47. Rintoul R C, Ritchie A J, Edwards J G, Waller D A, Coonar A S, et al. MesoVATS Collaborators. Efficacy and Cost of Video-Assisted Thoracoscopic Partial Pleurectomy Versus Talc Pleurodesis in Patients With Malignant Pleural Mesothelioma (MesoVATS): An Open-Label, Randomised, Controlled Trial. *Lancet*. 2014 Sep 20;384 (9948):1118-27.
48. Schwartz R, Lieberman- Cribin W, Wolf A, Flores R M, Taioli E. Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma. *BMC Cancer*. 2018 Nov 29;18 (1):1188.
49. Gaertner E, Zeren EH, Fleming MV, Colby TV, Travis WD. Biphasic synovial sarcomas arising in the pleural cavity. A clinicopathologic study of five cases. *Am J Surg Pathol* 1996; 20:36-45.
50. Chen S, Zhang K, Wan X, Chen Y, Ma S, Deng Q. The use of apatinib in treating primary pleural synovial sarcoma: A case report. *Medicine (Baltimore)*. 2019 Dec;98 (51).
51. Choi SH, Koh KP, Han JO, Choi JB. Primary malignant fibrous histiocytoma (MFH) of pleura: a case report. *Korean J Thorac Cardiovasc Surg* 2000; 33:770-2.
52. Cho KH, Park C, Hwang KE, Hwang YR, Seol CH, Choi KH, et al. Primary Malignant Fibrous Histiocytoma of the Pleura. *Tuberc Respir Dis (Seoul)*. 2013 May;74 (5):222-5.
53. Schallier D, Berendes BJ, Lefesvre P, Everaert H. Effective Treatment of Pleural Epitheloid Hemangioendothelioma with Pazopanib: A Case Report. *Anticancer Res*. 2016 Jan;36 (1):351-4.
54. Şahin E, KATRANCIOĞLU Ö. Plevranın Nadir Görülen Primer Tümörleri. *Plevra Hastalıkları ve Tedavisi*, Ed. Yücel O, Genç O. Matris Tanıtım Baskı Hizmetleri, 2011: 51-3.
55. Shiota H, Yasukawa T, Hirai A, Chiyo M, Yusa T, Hiroshima K, et al. Extraskelletal Osteosarcoma of the Pleura: report of a Case. *Ann Thorac Cardiovasc Surg*. 2013;19 (4):297- 301.
56. Chandak P, Hunt I, Rawlins R, Lucas S, Treasure T. Bone or pleura? Primary pleural osteosarcoma. *J Thorac Cardiovasc Surg*. 2007 Feb;133 (2):587-8
57. Kao YC, Chow JM, Wang KM, Fang CL, Chu JS, Chen CL. Primary pleural angiosarcoma as a mimicker of mesothelioma: a case report **VS**. *Diagnostic Pathology* 2011 6:130.
58. Uysal S, Kılıçgün A. Plevranın Benign Tümörleri ve Mezotelyoma Dışı Malign Tümörleri. *Güncel Göğüs Hastalıkları Serisi* 2015; 3 (3): 355-361
59. Sinha AK, Khanna A, Talwar D, Dbaral C. Primary pleural leiomyosarcoma- A rare entity. *Lung India*. 2017 Jan-Feb;34 (1):104-105.
60. Rais G, Raissouni S, Mouzount H, Aitelhaj M, Khoyaali S, Omrani FE, et al. Primary pleural leiomyosarcoma with rapid progression and fatal outcome: a case report. *J Med Case Rep*. 2012 Apr 5;6:101.
61. Bailey S.C, Head H.D. Pleural Chondrosarcoma. *Ann Thorac Surg* 1990;49:996-7.
62. Picchi E, Di Giuliano F, Ferrari D, Pistolesse CA, Garaci F, Floris R. Pleural thymoma: Radiological and histological findings. *Eur J Radiol Open*. 2018 Sep 5;5:147-152.
63. Vega F, Padula A, Valbuena JR, Stancu M, Jones D, Medeiros LJ. Lymphomas involving the pleura: A clinicopathologic study of 34 cases diagnosed by pleural biopsy. *Arch Pathol Lab Med* 2006;130: 1497-1502.
64. Steiropoulos P, Kouliatsis G, Karpathiou G, Popidou M, Froudarakis ME. Rare cases of primary pleural Hodgkin and non-Hodgkin lymphomas. *Respiratory* 2009;77: 459-463.
65. Sun ML, Shang B, Gao JH, Jiang SJ. Rare case of primary pleural lymphoma presenting with pleural effusion. *Thorac Cancer*. 2016 Jan;7 (1):145-50
66. Sigala I, Alevizopoulos N, Elefteriou K, Gianniou N, Kalomenidis I. Primary squamous cell carcinoma of the pleura treated with nivolumab. *Respirol Case Rep*. 2020 Feb 5;8 (2):e00516.